An RNA oligonucleotide drug that is being tested as a combination therapy in patients with pancreatic and colorectal cancers has produced positive data in a Phase 1 clinical study. Top-line results from the combination of NOX-A12 (olaptesed pegol) and Keytruda produced responses from patients whose cancers had progressed rapidly on prior therapy.
